PFEPfizerRunning, no new patients
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Prostate Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 599 (final count)
- Started
- May 12, 2021
- Main results expected
- Feb 18, 2026
- Fully finished
- Aug 28, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
radiological Progression-Free Survival
Measured over: randomization up to 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04821622 · record last updated 2026-11-05 · checked 2026-11-09 15:36 UTC